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Abstract 24 
The aim of this study was to investigate suitability of natural and synthetic smectite clay 25 
matrices as a drug delivery carrier for the development of amorphous solid dispersions (ASD). 26 
Indomethacin (IND) was processed with two different smectite clays, natural-magnesium 27 
aluminium and synthetic-lithium magnesium sodium silicates, using Hot Melt Extrusion 28 
(HME) to prepare solid dispersions. Scanning electron microscopy (SEM), Powdered X-ray 29 
diffraction (PXRD), Differential scanning calorimetry (DSC) were used to examine the 30 
physical form of the drug. Energy dispersive X-ray spectroscopy (EDX) was used to investigate 31 
the drug distribution and Attenuated Total Reflectance-Fourier transform infrared (ATR-32 
FTIR) spectroscopic analysis was done to detect any chemical interaction between these two 33 
kinds. Both, PXRD and DSC analysis showed that drug-clay solid dispersion contained IND 34 
in amorphous form. Energy dispersive X-ray (EDX) analysis showed a uniform IND dispersion 35 
in the extruded powders. ATR-FTIR data presented possible drug and clay interactions via 36 
hydrogen bonding. In-vitro drug dissolution studies revealed a lag time of about two hours in 37 
the acidic media and a rapid release of IND at pH 7.4. The work demonstrated that preparation 38 
of amorphous solid dispersion using inorganic smectite clay particles can effectively increase 39 
the dissolution rate of IND. 40 










To date, numerous drug molecules have been discovered with higher molecular weight, greater 51 
lipophilicity, and minimal water solubility which often cause difficulties during their 52 
pharmaceutical manufacturing process (1,2). Primarily, these factors are liable for an 53 
inadequate drug dissolution and their limited bioavailability. At the same time, this rise of 54 
poorly water soluble drugs also pushed for innovative strategies to overcome solubility related 55 
issues i.e. salt formation (3), co-crystals (4), pro-drugs formation (5), solid lipid nanoparticle 56 
(6), amorphous solid dispersion (7) etc.  Among these, amorphous solid dispersion- invented 57 
by Sekiguchi and Obi in 1961, has shown promising results for improving dissolution rates of 58 
poorly water soluble compounds (8). This technique allows to disperse an insoluble drug in a 59 
water soluble carrier at molecular level, enabling it to greatly enhance the total specific surface 60 
area which ultimately increases the dissolution rate and bioavailability. 61 
Clays are water soluble silicate compounds, generally used as an excipient in pharmaceutical 62 
formulations i.e. lubricant, desiccant, disintegrant, diluent, binder, opacifier, as well as 63 
emulsifying, thickening, isotonic agent, anticaking agent, flavour corrector and carrier of active 64 
ingredients etc. (9–11). Among many varieties, smectite clays are particularly well known for 65 
their water solubility, dispersivity, swelling capacity and relatively high specific surface area 66 
(12). Takahashi and Yamaguchi believed that swelling ability of clay silicates and their 67 
complex formation ability is beneficial to act as a drug carrier and solubilise poorly water-68 
soluble drugs (13). Authors prepared griseofluvin-clay hybrids with less than 5% clay complex 69 
which demonstrated higher solubility compare to the pure drug. Goncalbes et al. also explored 70 
the use of phyllosilicate clay mineral to increase the solubility of olanzapine (14). Prepared 71 
phyllosilicate and olanzapine complex showed around 50% increase of dissolution rate within 72 
first 60 minutes (min) of the study. 73 
Smectite clays such as natural-Veegum (VF) and synthetic-laponite (LP) are also widely used 74 
in the pharmaceuticals as stabilising and suspending agent, rheology modifier as well as texture 75 
enhancer (15,16). Primarily, these high swelling clays contain Na+ ions in between their 76 
interlayer spacing, enabling them to adsorb up to 32 layers of water molecules (17). Adebisi et 77 
al. found that VF increases the dissolution rate of theophylline from the tablet matrices (15). 78 
LP nanoparticles were used to enhance the solubility of itraconazole upto 75%, reported by 79 
Jung et al. (18). Such investigations of clay mineral clearly indicating possibilities to improve 80 
the dissolution rate of indomethacin (IND). The rationale for using clay silicates as a 81 
dissolution rate enhancing component was the hydrophilic nature of silica particles. Silica 82 
particles contain abundant hydroxyl groups and exceptionally high specific surface area that 83 
enables drug particles to interact instantaneously with the water molecules through hydrogen 84 
bonding. Bahl D. et al. co-grinded also IND with pharmaceutical silicates to enhance the 85 
dissolution rate of the drug (19).  86 
IND is a non-steroidal, anti-inflammatory drug belongs to BCS class II category with a 87 
solubility of only 0.937 mg/L in water (20). Such a water insoluble drug often shows low 88 
absorption and poor bioavailability. Also limited solubility of this drug may also increase the 89 
residence time in the gastro-intestinal tract which may irritate the gastric mucosal layer (21). 90 
Hence, IND formulation preparation with an improved dissolution rate is at utmost importance 91 
to the pharmaceutical manufacturing industry. 92 
The use of hot melt extrusion as a processing technology for the development of amorphous 93 
solid dispersions is well – known in pharmaceutical industry. HME possesses many advantages 94 
such as cost effective, high throughput, minimal waste loss and solvent free processing 95 
technology. There are numerous studies where HME has been employed for preparing 96 
amorphous solid dispersion with improved dissolution rates of poorly water soluble 97 
compounds. Although polymeric solid dispersions of IND have been reported previously (22), 98 
the efficacy of clay minerals as an inorganic carrier is yet to be explored. Hence, the current 99 
study investigates the feasibility of natural and synthetic smectite clay silica particles for solid 100 
dispersion of IND to improve the dissolution rates using TSE. 101 
MATERIALS AND METHODS 102 
Materials 103 
Veegum F® (Magnesium aluminium metasilicate) and Laponite RDS® (Lithium magnesium 104 
sodium silicate) clay minerals were kindly donated by Vanderbilt minerals llc. (USA) and BYK 105 
additives ltd. (Germany) respectively. Indomethacin was purchased from Tokyo chemical 106 
industries (Japan), with a purity of >98.0% and all the reagents were used as received. Other 107 
chemical reagents such as hydrochloric acid, di-Potassium hydrogen orthophosphate, 108 
Potassium di-hydrogen phosphate, acetonitrile (HPLC grade), Ortho-phosphoric acid were 109 
purchased from Fisher scientific UK and used as received. 110 
Continuous possessing of ASD using HME 111 
IND formulations shown in Table I. were blended using a Turbula TF2 Mixer (Switzerland) 112 
for 10 min. Then solid dispersions of IND were prepared using a 10 mm Rondol Microlab twin 113 
screw extruder (France) with a 25:1 L/D ratio. Standard screw configuration with two kneading 114 
zones and three conveying zone was used to disperse solid drug materials in the clay matrices 115 
(shown in Fig. 1). The extruder barrel has five different heating zones where 80- 140- 170- 116 
170- 30 ºC (from feed to die) temperature were used to established ASD. Extrusions were 117 
processed using 25% or 0.1 kg/hr feed rate with a screw speed of 50 rpm.  118 
Table I. Formulations used for continuous solid dispersion using HME 119 
Formulation IND (%) VF (%) LP (%) 
VIN-20 20.0 80.0 - 
VIN-40 40.0 60.0 - 
LIN-20 20.0 - 80.0 
LIN-40 40.0 - 60.0 
*V- Veegum F, L- Laponite RDS, IN- Indomethacin 120 
 121 
Fig. 1. Photograph of screw configuration. 122 
Morphology analysis of extrudates 123 
SEM was used to study the surface morphology of the prepared extrudates. All the samples 124 
were mounted on an aluminium stub using adhesive carbon tape and placed in a low humidity 125 
chamber prior to analysis. Samples were then examined using a Cambridge Instruments (S630, 126 
UK), SEM operating at an accelerating voltage of 1.0 kV. Particle size distributions of the 127 
extruded powders were determined using a Mastersizer 2000 laser diffraction instrument 128 
(Malvern Instruments, UK) with a dry powder sample dispersion accessory (Scirocco 2000) 129 
and pressure at 2 bar and a vibration feed rate of 50%. Samples were examined in triplicate and 130 
Mastersizer 2000 software was used for data evaluation.  131 
PXRD analysis 132 
Crystalline structure of the pure and extruded materials were investigated using a Bruker D8 133 
Advance (Germany) X-ray powder diffractometer in 2-theta mode. The instrument was 134 
equipped with a copper anode at 40 KV, parallel beam Goebel mirror, 0.2 mm exit slit and a 135 
LynxEye position sensitive detector with 3º opening (Lynxiris at 6.5 mm). Each sample was 136 
prepared using a PMMA (Poly-methyl-methacrylate) sample holder which was scanned from 137 
2 to 56 º2θ with a step size 0.02 º2θ, counting time 0.1 s per step and a rotation of 15 rpm.  138 
DSC analysis 139 
Thermal analysis were done using a Mettler-Toledo 823e (Switzerland) differential scanning 140 
calorimeter on the drug and extruded samples. About 4 mg of samples were placed in a sealed 141 
aluminium pan with pierced lids. Prepared samples were heated from 30 to 230 ºC at a heating 142 
rate of 10 ºC/min under dry nitrogen atmosphere.  143 
ATR-FTIR analysis 144 
Pure drug, clays and extruded formulations were also separately compressed into a thin disk 145 
using a SPECAC hydraulic press and  investigated using a Perkin Elmer Spectrum Two ATR-146 
FTIR spectrometer (USA) between 450 and 4000 cm-1 wavenumbers, with 10 scans at a 147 
resolution of 8 cm-1. Samples were then fixed onto an aluminium stub using double sided 148 
carbon adhesive tape for elemental analysis using Energy dispersive X-ray (EDX) 149 
spectroscopy. 150 
EDX analysis 151 
EDX spectroscopy was obtained using a JEOL JSM- 5310LV (JAPAN) instrument. 152 
Micrographs were collected at 20 kV accelerating voltage, 20 mm working distance, 15 spot 153 
size and using a backscattered electron detector. Elemental mapping was also studied using an 154 
Aztec X-ray microanalysis system with X-MaxN detector from Oxford instrument (UK). 155 
In-vitro dissolution study 156 
Release of IND from the clay matrices were also examined using a Varian 705 DS (USA) 157 
paddle apparatus at 100 rpm and 37 ºC. At first, 750 mL 0.1 N HCl solution of pH 1.2 were 158 
used to study the drug release for 2 hr. After that 150 mL of phosphate buffer was added and 159 
pH was adjusted to 7.4 using NaOH solution. Samples were collected at 15, 30, 60, 90, 120 160 
min time interval from both pH and dissolution studies were also performed in triplicate. 161 
Samples were then analysed using a high performance liquid chromatographic system provided 162 
by Agilent Technologies, 1200 series (USA). IND was analysed using a HYCHROME 163 
S5ODS2-4889 (5×150×4 mm) column and an UV detector at a wavelength of 214 nm. The 164 
mobile phase were prepared using acetonitrile: water: Ortho-phosphoric acid (49.5: 49.3: 0.2 165 
v/v) and pumped at a flow rate of 1.5 mL/min. Abovementioned specification showed a 112 to 166 
114 bar of column back pressure with a retention time of 3.00 ± 0.1 min. Calibration curve was 167 
also prepared using 20, 40, 60, 80 and 100 µg/mL concentrated ethanolic solution of IND. 168 
RESULTS AND DISCUSSIONS 169 
In the current study, solid dispersions of IND in inorganic clay silicates were prepared by HME 170 
and the suitability of clay silicates were also investigated as a carrier for poorly water-soluble 171 
pharmaceutical actives. To optimise the processing conditions, various parameters such as 172 
temperature, screw speed, feed rate were taken into careful considerations. Extrusion 173 
temperature profile optimisation played a key role in the development of ASDs. Formulations 174 
were also designed carefully to investigate the efficiency of HME processing on layered clay 175 
silicates and drug molecules. Literature suggests, ASD prepared with HME technology 176 
contains amorphous form of drug particles with a higher Gibbs free energy (23,24). In this 177 
study, both natural and synthetic grades of hydrophilic smectite clays were used to increase the 178 
wettability of IND leading to an improved drug dissolution rate. The drug and clay ratio was 179 
further investigated to evaluate the effect on the dissolution rate improvement.  The absence of 180 
the die during extrusion led to the formation of free-flowing extruded powders in the form of 181 
micro-particles which in turn reduced downstream processing. The powders were collected for 182 
further physicochemical characterisation with no need for milling.  183 
Morphology analysis of extrudates 184 
The morphology of bulk drug and extruded formulations were analysed using SEM. Fig. 2. (a, 185 
b) shows bulk IND particles which present plate-shape morphology. On the other hand, in Fig. 186 
2. (c, d) the obtained solid dispersions showed the absence of crystalline IND as a result of the 187 
extrusion process optimisation. This suggests the adsorption of melted drug molecules in the 188 
silica porous network which not only facilitates the transformation of drug into amorphous 189 
state but also result in improved powder flowability for the development of the finished dosage 190 
form i.e. tablet preparation using direct compression method or capsules preparation (25). In 191 
addition, the extruded dispersions appear as granular micro-agglomerates due to the absence 192 
of the extrusion die. Extruded powders were then analysed using particle size analyser and 193 
results has been presented in Fig. 2. (e, f). As it can be seen a large percentage of fine particles 194 
was observed in the bulk clays prior to extrusion processing.  In the drug loaded clays, a 195 
significant reduction of the fines was detected, and the formation of larger agglomerates took 196 
place in agreement with SEM analysis.  In Fig. 2. e, can also be seen that higher drug loadings 197 
(40%) facilitated the formation of larger granules with sizes varying from 100 – 500 μm. 198 
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Fig. 2. (Top) SEM micrographs of (a-b) pure IND, c- VIN and d- LIN extruded formulations. 203 
(Bottom) Particle size distribution of VIN, LIN extruded formulations against pure clay. 204 
PXRD analysis 205 
The physical state of the crystalline drug, clay and their extruded formulations were examined 206 
using PXRD analytical technique and shown in Fig. 3. Diffractogram of crystalline IND 207 
showed peaks with sharp intensity at 9.1, 10.6, 11.7, 15.8, 18.6, 20.8, 25.6 and 28.3 º2θ. Pure 208 
clays, VF and LP also showed their primary peaks at 7.4, 19.9, 21.9 º2θ and 6.5, 20.1, 33.3 º2θ 209 
respectively. Interlayer spacing for pure VF at 7.4 º2θ= 11.9 Å and LP at 6.5 º2θ= 13.6 Å was 210 
found using Bragg’s law (nλ=2dsinθ). Although the interlayer spacing of anhydrous smectite 211 
clay should be  ̴ 10 Å, presence of homogeneous water molecules increases the interlayer 212 
spacing between two aluminosilicate sheets (26). The broad interlayer spacing also indicates 213 
the poor organisation of silicate layers in the structure. PXRD pattern of VIN and LIN 214 
formulations showed higher basal spacing compare to the pure clays. In particular, the basal 215 
spacing of VIN was indistinguishable in obtained the diffractogram.  The IND – VIN and IND 216 
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results suggest the formation of amorphous solid dispersions probably due to stronger 218 
interactions between the drug and the clay at molecular level. Interestingly, the extruded 219 
formulations appeared partially amorphous when extrusion temperatures were set below 160 220 
oC. Stability studies were also performed at 25 °C/ 60% RH for 12 months and showed that 221 
extruded IND-silicate dispersions were relatively stable with no more than 10±2% increase in 222 
their crystallinity compared to fresh extruded batches. 223 
 224 
Fig. 3. PXRD diffractograms of bulk IND, smectite clays and extruded formulations. 225 
DSC analysis 226 
Thermal transitions of bulk drug, clay and extruded formulations were studied using DSC 227 
analysis shown in Fig. 4. The IND thermogram showed a sharp endothermic peak at 162 ºC 228 
representing the melting point of the pure crystalline IND (21,27). In contrast, both of the clays 229 
did not present any melting endotherms within the investigated temperature range. However, 230 
both VF and LP showed endothermic events at 35-125 ºC and 35-165 ºC respectively which 231 
corresponds to the removal of  the surface bound water molecules from the clay (28). 232 
 233 
Fig. 4. Thermal transitions of pure IND, VF, LP, VIN and LIN extruded formulations.  234 
Similarly, thermograms of VIN and LIN extruded formulations presented water loss at 30-110 235 
ºC with lower enthalpy values due to the HME processing at 170 ºC.  Fig. 4 also shows that the 236 
absence of IND melting endothermic peak in VIN and LIN formulations (22,27). Most 237 
importantly, the VIN and LIN thermograms presented endothermic events at 47.91 and 56.57 238 
ºC respectively which might correspond to the drug’s Tg where for the amorphous IND is 239 
around at 46 ºC. However, the observed endothermic events showed  a shift of  Tg to higher 240 
temperatures which is not unusual and it has been reported that clays can shift glass transitions 241 
of  drug or polymeric blends (29,30).  242 
 243 
 244 
ATR- FTIR spectroscopic analysis 245 
ATR-FTIR spectra of pure drug, clays and drug-clay complexes are shown in Fig. 5. Both VF 246 
and LP clays showed a broad band at 3400 cm-1 due to –OH stretching band for interlayer 247 
adsorbed water (31). The band around 3640 and 3690 cm-1 is due to the Al-OH and Si-OH 248 
stretching respectively (32). The presence of several hydroxyl groups in the clay contributes to 249 
the broadness of this stretching band. The absorption peak at 1650 cm-1 belongs to the bending 250 
mode of hydroxyl group of the interlayer water molecules.  251 
 252 
Fig. 5. ATR-FTIR spectrum of pure IND, VF, LP and VIN, LIN extruded formulations.   253 
The characteristic peak at 1000 cm-1 is related to the Si-O stretching vibration of the clay 254 
(33,34). IND spectra showed C=O stretching vibration in the range of 1600-1750 cm-1 while 255 
the peak at 1694 cm-1 is the characteristic of polymorphic Form – I of the drug substance (35). 256 
IND presents also a carbonyl and benzoyl groups at 1694 cm-1 and 1688 cm-1 respectively. 257 
Extruded VIN and LIN formulations showed that  stretching vibration of IND at 1694 cm-1 was 258 
shifted to around 1670 cm-1 which indicates that crystalline structure of IND has transformed 259 
to the amorphous state (36,37). The changes in the carbonyl spectral region indicate an 260 
alteration in the drug’s molecular state where the shifting of carbonyl stretching is attributed to 261 
the disruption of IND-IND molecular interactions in its crystal structure. The bonding energy 262 
of carbonyl oxygen from IND decreases after adsorption of the drug onto the clay silicate, 263 
resulting a weakening of the carbonyl peak at 1670 cm-1. Finally, the shift of the carbonyl band 264 
suggests possible H-bonding formation with the clay platelets (35).  265 
EDX spectroscopic analysis 266 
Microscopic analysis and elemental mapping were studied for the drug–clay solid dispersions 267 
to evaluate the presence and distribution of IND in the clay matrices. As shown in Fig. 6, 268 
micrographs were collected using back-scattered electrons and corresponding EDX elemental 269 
maps of Na, Si and Cl showing variation of clay and drug distribution within the extruded 270 
samples. Clays such as VF primarily contain Na, Mg, Ca, Si  and LP contains Na, Mg, Li, Si 271 
atoms in its structure (38,39). Heavier elements in a molecule appears brighter in a 272 
backscattered electron micrograph compared to the lighter atoms. The above micrographs in 273 
grayscale clearly explains the homogeneous distribution of VF and  agglomerated LP clay 274 
distribution in the VIN and LIN dispersions respectively. X-ray elemental mapping of Na and 275 
Si (presented in yellow and red respectively, top) also confirmed homogenous distribution of 276 
VF in the VIN complex. In contrast, LIN extrudates exhibited a more inhomogeneous 277 
dispersion with areas high in Na and P (P EDX map not shown) indicating an additional phase 278 
in the drug-clay matrix (shown in the Na and Si ion map, bottom). 279 
   
 
    
Fig. 6. Elemental analysis of extruded formulations, collected using SEM (Top – BSE 280 
micrograph of VIN extrudates and its Na, Si, Cl mapping; Bottom – BSE micrograph of LIN 281 
extrudates and its Na, Si, Cl mapping) 282 
Furthermore, chemical structure of IND contains chlorine (Cl) atom in its chemical structure 283 
while both the clays have no Cl present. Therefore, an X-ray elemental mapping of Cl as a 284 
marker will reveal the homogenity of drug distribution. Mapping data of Cl (presented in green) 285 
shows that VIN extrudate contains uniform drug distribution where else LIN complex shows 286 
presence of dark area, indicating a less uniform clay drug distribution. These type of poly-287 
dispersions may be minimised by optimising the processing parameters during extrusion.  288 
In-vitro dissolution study 289 
The in-vitro dissolution study was conducted using extruded drug-clay complex formulations 290 
and the bulk drug substance. The results of the study are shown in Fig. 7. The use of smectite 291 
clays for the development of amorphous solid dispersions facilitated controlled release of the 292 
drug substance for both formulations. As shown in Fig. 7, dissolution studies presented a lag 293 
time with no IND release in acidic (pH 1.2) dissolution media. After 120 min, the pH was 294 
adjusted to 7.4 and bulk IND presented   33% and 50% drug release at 15 min and 120 min 295 
respectively. 296 
In contrast, clay-drug complexes showed a burst release of IND from the clay matrices at 135 297 
min. The VIN 20 and LIN 20 solid dispersions showed almost 60% drug release within the first 298 
15 min. At higher drug loadings, LIN 40 also presented rapid dissolution rates at 57% while 299 
the VIN 40 at 47% respectively. This could be attributed to the higher particle size of VIN 40 300 
and LIN 40 formulations.  301 
 302 
Fig. 7. In-vitro dissolution profiles of pure IND and HME extruded formulations at pH 1.2 (0-120 303 
min) and pH 7.4 (120-240 min). 304 
Overall, the increase of dissolution rates could be attributed to several factors such as the 305 
amorphous form of IND molecules, particle size and H-bonding due to the drug-clay 306 
interactions.  The clay particles may have shown some ionic interactions between adsorbate 307 
and adsorbent surface during the release study at pH 7.4 (40,41). As IND is a weak acid, the 308 
highly negative surface charge of the clay at pH 7.4, might have induced dissociation of IND 309 
molecule resulting in burst release. In addition, the negatively charged smectite particles 310 
(negative charges on the border plane of the smectite layers) may have also created repulsive 311 
forces to  IND that led to drug desorption from the clay matrices (42,43). 312 
 Although, a burst release of IND was initially observed, it can be seen in Fig. 7 that IND 313 
dissolution rates decreased over time. This can be attribute to possible IND recrystallisation 314 
where the amophous drug crystallized in the dissolution media due to the generated 315 
superaturation solution (25,44). Nevertheless, it can be concluded that the dissolution rate 316 
improvement of IND was achieved not only by conversion of its physical form but also through 317 
the specific chemical environment created by clay silicates. 318 
CONCLUSIONS 319 
The current study about smectite clays were introduced as an alternative drug carrier for the 320 
formation of IND amorphous solid dispersions.  PXRD and DSC studies demonstrated that 321 
IND was converted into amorphous form while EDX analysis revealed excellent IND content 322 
uniformity in the clay matrices due to extrusion processing. The extruded ASD presented 323 
controlled release with rapid IND dissolution rates in alkaline media for drug loadings varying 324 
from 20 to 40%. In conclusion, smectite clays can be used as a drug carriers for the 325 
development of ASDs at up to 40% high drug loadings. 326 
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